Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Smolen

Showing results (1011-1020 of 1,467) with videos related to

Pageof 147
Sort By:
Annals of the Rheumatic Diseases|December 21, 2012
The role of biosimilars in the treatment of rheumatic diseasesThomas Dörner, Vibeke Strand, Gilberto Castañeda-Hernández, et al.
Arthritis Research & Therapy|January 29, 2015
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER studyJosef S Smolen, Jonathan Kay, Mittie Doyle, et al.
Annals of the Rheumatic Diseases|November 18, 2004
Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cellsJ Grisar, M Aringer, M D Köller, et al.
Arthritis and Rheumatism|September 2, 2006
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateR N Maini, P C Taylor, J Szechinski, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritisMarkus H Hoffmann, Jonatan Tuncel, Karl Skriner, et al.
Arthritis Research & Therapy|August 16, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisJosef S Smolen, Young Mo Kang, Wan-Hee Yoo, et al.
The Journal of Trauma and Acute Care Surgery|March 23, 2023
Early surgical stabilization of rib fractures for flail chest is associated with improved patient outcomes: An ACS-TQIP reviewAlexander Simmonds, Julia Smolen, Mathew Ciurash, et al.
Annals of the Rheumatic Diseases|September 18, 2012
Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohortIuliia Biliavska, Tanja A Stamm, Jose Martinez-Avila, et al.
Clinical and Experimental Rheumatology|August 16, 2002
Induction of anti-RA33 hnRNP autoantibodies and transient spread to U1-A snRNP complex of spliceosome by idiotypic manipulation with anti-RA33 antibody preparation in miceG Steiner, O Shovman, K Skriner, et al.
The Journal of Rheumatology|July 26, 2002
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formationJohannes Grisar, Peter M Bernecker, Martin Aringer, et al.
Pageof 147

Showing results (1011-1020 of 1,467) with videos related to

Sort By:
Pageof 147
Annals of the Rheumatic Diseases|December 21, 2012
The role of biosimilars in the treatment of rheumatic diseasesThomas Dörner, Vibeke Strand, Gilberto Castañeda-Hernández, et al.
Arthritis Research & Therapy|January 29, 2015
Golimumab in patients with active rheumatoid arthritis after treatment with tumor necrosis factor α inhibitors: findings with up to five years of treatment in the multicenter, randomized, double-blind, placebo-controlled, phase 3 GO-AFTER studyJosef S Smolen, Jonathan Kay, Mittie Doyle, et al.
Annals of the Rheumatic Diseases|November 18, 2004
Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cellsJ Grisar, M Aringer, M D Köller, et al.
Arthritis and Rheumatism|September 2, 2006
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexateR N Maini, P C Taylor, J Szechinski, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
The rheumatoid arthritis-associated autoantigen hnRNP-A2 (RA33) is a major stimulator of autoimmunity in rats with pristane-induced arthritisMarkus H Hoffmann, Jonatan Tuncel, Karl Skriner, et al.
Arthritis Research & Therapy|August 16, 2020
Radiographic progression based on baseline characteristics from TNF inhibitor biosimilar studies in patients with rheumatoid arthritisJosef S Smolen, Young Mo Kang, Wan-Hee Yoo, et al.
The Journal of Trauma and Acute Care Surgery|March 23, 2023
Early surgical stabilization of rib fractures for flail chest is associated with improved patient outcomes: An ACS-TQIP reviewAlexander Simmonds, Julia Smolen, Mathew Ciurash, et al.
Annals of the Rheumatic Diseases|September 18, 2012
Application of the 2010 ACR/EULAR classification criteria in patients with very early inflammatory arthritis: analysis of sensitivity, specificity and predictive values in the SAVE study cohortIuliia Biliavska, Tanja A Stamm, Jose Martinez-Avila, et al.
Clinical and Experimental Rheumatology|August 16, 2002
Induction of anti-RA33 hnRNP autoantibodies and transient spread to U1-A snRNP complex of spliceosome by idiotypic manipulation with anti-RA33 antibody preparation in miceG Steiner, O Shovman, K Skriner, et al.
The Journal of Rheumatology|July 26, 2002
Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formationJohannes Grisar, Peter M Bernecker, Martin Aringer, et al.
Pageof 147